In a combined in vitro and in vivo experiment, Zhou and others (2022) developed a new nanocarrier called chitosan-gelatin-epigallocatechin-3-gallate (Ch-G-EGCG) for systemic si‐TMEM44‐AS1 delivery that can silence TMEM44‐AS1 gene expression in gastric cancer cells and boost 5‐FU sensitivity in gastric cancer cells (Zhou et al., 2022). This evidence concerns the gene TMEM44 and gastric cancer.